The network pharmacology and molecular docking analyses predicted that HCS inhibits the growth of and progression of BRCA by inactivating the PI3K-Akt/mTOR signaling pathway, which is known to regulate the proliferation, apoptosis, and migration of tumor cells. The gene discussed is PIK3CD; the disease is neoplasm.